Recent studies have revealed that antiepileptic drug phenytoin (PHT) inhibits not only voltage-gated sodium channels (VGSCs), but also α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), particularly calcium-impermeable (CI) ones. However, the benefit of this additional action for seizure control has not been fully understood. Here, we used three experimental seizure models to compare the efficacy of PHT and PHT derivatives, which showed different profiles of activity against VGSC/CI-AMPAR in the recent in vitro studies. Among tested compounds, we selected Hyd-8 (diphenylthiohydantoin), active against both targets with enhanced activity against CI-AMPARs, Hyd-5, acting only on VGSCs, and Hyd-1, inactive against both. The compounds were administered intraperitoneally to Wistar rats, further exposed to pentylenetetrazole (PTZ) and hyperbaric oxygen (HBO2) seizures, and to Krushinsky-Molodkina (KM) audiogenic rats before the further audiogenic seizure stimulations. Behavioral side effects were assessed after the drug injections and seizure stimulations by means of the open field test (OFT). In the HBO2 model, all PHT-related compounds were ineffective and shortened seizure latency. In PTZ and audiogenic seizure models, Hyd-5 and Hyd-8 showed anticonvulsant activity, with Hyd-8 generally demonstrating more beneficial profile. OFT showed that PHT derivatives did not share the behavior-suppressing effect of PHT, although Hyd-8 induced agitation in KM rats, likely reflecting strain-specific behavior. These results suggest that Hyd-8 is a promising antiseizure candidate, whereas seizures triggered by oxidative stress require alternative therapeutic strategies.